Recombinant human growth hormone: Rationale for use in the treatment of HIV-associated lipodystrophy

BioDrugs

Volumn 22, Issue 2, 2008, Pages 101-112

  Benedini, Stefano ^a   Terruzzi, Ileana ^a   Lazzarin, Adriano ^a   Luzi, Livio ^a,b,c  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c Amino Acids and Stable Isotopes Laboratory   (Italy)

Author keywords

HIV associated lipodystrophy syndrome, treatment; Somatropin, therapeutic use

Indexed keywords

HUMAN GROWTH HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; PROTEINASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ARTHRALGIA; ATHEROSCLEROSIS; BODY COMPOSITION; CANCER SURVIVAL; CARDIOVASCULAR RISK; CARPAL TUNNEL SYNDROME; CHILDHOOD CANCER; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG BINDING; DRUG MECHANISM; DYSLIPIDEMIA; EXERCISE; FLUID RETENTION; GENERALIZED EDEMA; GLUCOSE INTOLERANCE; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE; HEALTH HAZARD; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCOAGULABILITY; HYPERGLYCEMIA; INCIDENCE; INTRAABDOMINAL FAT; LIPID STORAGE; LIPOATROPHY; LIPODYSTROPHY; LOW DRUG DOSE; MYALGIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PARESTHESIA; PERIPHERAL EDEMA; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SIGNAL TRANSDUCTION; TUMOR GROWTH;

EID: 41049093322     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200822020-00003     Document Type: Review

References (112)

1. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51-8
2. Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999; 13: 1659-67
3. van der Valk M, Allick G, Weverling GJ, et al. Markedly diminished lipolysis and partial restoration of glucose metabolism, without changes in fat distribution after extended discontinuation of protease inhibitors in severe lipodystrophic human immunodeficient virus-1-infected patients. J Clin Endocrinol Metab 2004; 89 (7): 3554-60
4. Ducobu J, Payen MC. Lipids and AIDS. Rev Med Brux 2000; 21: 11-7
5. Haugaard SB, Andersen O, Pedersen SB, et al. Tumor necrosis factor alpha is associated with insulin-mediated suppression of free fatty acids and net lipid oxidation in HIV-infected patients with lipodystrophy. Metabolism 2006; 55 (2): 175-82
6. Nolan D. Metabolic complications associated with HIV protease inhibitor therapy. Drugs 2003; 63: 2555-74
7. Renard E, Fabre J, Paris F, et al. Syndrome of body fat redistribution in HIV-1-infected patients: relationships to cortisol and catecholamines. Clin Endocrinol (Oxf) 1999; 51: 223-30
8. Rietschel P, Hadigan C, Corcoran C, et al. Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy. J Clin Endocrinol Metab 2001; 86: 504-10
9. Koutkia P, Canavan B, Breu J, et al. Growth hormone (GH) responses to GH-releasing hormone-arginine testing in human immunodeficiency virus lipodystrophy. J Clin Endocrinol Metab 2005; 90 (1): 32-8
10. Murray RD, Adams JE, Shalet SM. Adults with partial growth hormone deficiency have an adverse body composition. J Clin Endocrinol Metab 2004; 89: 1586-91
11. Boguszewski CL, Meister LH, Zaminelli DC, et al. One year of GH replacement therapy with a fixed low-dose regimen improves body composition, bone mineral density and lipid profile of GH-deficient adults. Eur J Endocrinol 2005; 152: 67-75
12. Luzi L, Perseghin G, Tambussi G, et al. Intramyocellular lipid accumulation and reduced whole body lipid oxidation in HIV lipodystrophy. Am J Physiol Endocrinol Metab 2003 Feb; 284 (2): E274-80
13. Luzi L, Meneghini E, Oggionni S, et al. GH treatment reduces trunkal adiposity in HIV-infected patients with lipodystrophy: a randomized placebo-controlled study. Eur J Endocrinol 2005; 153 (6): 781-9
14. D'Amico S, Shi J, Sekhar RV, et al. Physiologic growth hormone replacement improves fasting lipid kinetics in patients with HIV lipodystrophy syndrome. Am J Clin Nutr 2006; 84 (1): 204-11
15. Esposito GJ, Thomas SG, Kingdon L, et al. Comparison of body composition assessment methods in patients with human immunodeficiency virus-associated wasting receiving growth hormone. J Clin Endocrinol Metab 2006; 91 (8): 2952-9
16. Andersen O, Haugaard SB, Flyvbjerg A, et al. Low-dose growth hormone and human immunodeficiency virus-associated lipodystrophy syndrome: a pilot study. Eur J Clin Invest 2004; 34 (8): 561-8
17. Kotler DP, Muurahainen N, Grunfeld C, et al. Serostim in Adipose Redistribution Syndrome Study Group. Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients. J Acquir Immune Defic Syndr 2004; 35: 239-52
18. Benavides S, Nahata MC. Pharmacologic therapy for HIV-associated lipodystrophy. Ann Pharmacother 2004; 38: 448-57
19. Driscoll SD, Meininger GE, Lareau MT, et al. Effects of exercise training and metformin on body composition and cardiovascular indices in HIV-infected patients. AIDS 2004; 18: 465-73
20. Thomas SG, Esposito JG, Ezzat S. Exercise training benefits growth hormone (GH)-deficient adults in the absence or presence of GH treatment. J Clin Endocrinol Metab 2003; 88: 5737-8
21. Jorgensen JO, Krag M, Kanaley J, et al. Exercise, hormones, and body temperature regulation and action of GH during exercise. J Endocrinol Invest 2003; 26: 838-42
22. Thomas SG, Esposito JG, Ezzat S. Exercise training benefits growth hormone (GH)-deficient adults in the absence or presence of GH treatment. J Clin Endocrinol Metab 2003; 88 (12): 5734-8
23. de Vos AM, Ultsch M, Kossiakoff AA. Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science 1992; 255: 306-12
24. Frank SJ. Growth hormone signalling and its regulation: preventing too much of a good thing. Growth Horm IGF Res 2001; 11: 201-12
25. Leung DW, Spencer SA, Cachianes G, et al. Growth hormone receptor and serum binding protein: purification, cloning and expression. Nature 1987; 330: 537-43
26. Baumann G, Stolar MW, Amburn K, et al. A specific growth hormone-binding protein in human plasma: initial characterization. J Clin Endocrinol Metab 1986; 62: 134-41
27. Argetsinger LS, Carter-Su C. Mechanism of signaling by growth hormone receptor. Physiol Rev 1996; 76 (4): 1089-107
28. Xu BC, Wang X, Darus CJ, et al. Growth hormone promotes the association of transcription factor STAT5 with the growth hormone receptor. J Biol Chem 1996; 271 (33): 19768-73
29. Endo TA, Masuhara M, Yokouchi M, et al. A new protein containing an SH2 domain that inhibits JAK kinases. Nature 1997; 387 (6636): 921-4
30. Greenhalgh CJ, Rico-Bautista E, Lorentzon M, et al. SOCS2 negatively regulates growth hormone action in vitro and in vivo. J Clin Invest 2005; 115 (2): 397-406
31. Brown RJ, Adams JJ, Pelekanos RA, et al. Model for growth hormone receptor activation based on subunit rotation within a receptor dimer. Nat Struct Mol Biol 2005; 12: 814-21
32. Carter-Su C, Rui L, Herrington J. Role of the tyrosine kinase JAK2 in signal transduction by growth hormone. Pediatr Nephrol 2000; 14 (7): 550-7
33. Richelsen B, Pedersen SB, Borglum JD, et al. Growth hormone treatment of obese women for 5 wk: effect on body composition and adipose tissue LPL activity. Am J Physiol 1994; 266: E211-6
34. Nam SY, Lobie PE. The mechanism of effect of growth hormone on preadipocyte and adipocyte function. Obes Rev 2000; 1 (2): 73-86
35. Simha V, Garg A. Lipodystrophy: lessons in lipid and energy metabolism. Curr Opin Lipidol 2006; 17 (2): 162-9
36. Reue K, Phan J. Metabolic consequences of lipodystrophy in mouse models. Curr Opin Clin Nutr Metab Care 2006; 9 (4): 436-41
37. Kravcik S. HIV lipodystrophy: a review. HIV Clin Trial 2000; 1 (3): 37-50
38. Hoffmann C, Rockstroh JK, Kamps BS. HIV medicine 2005. Cologne: Steinhäuser Verlag, 2005
39. Martinez E, Mocroft A, Garcia-Viejo MA, et al. Risk of lipodystrophy in HIV-1 infected patients treated with protease inhibitors: a prospective cohort study. Lancet 2001; 357: 592-8
40. Viganò A, Mora S, Testolin C, et al. Increased lipodystrophy is associated with increased exposure to highly active antiretroviral therapy in HIV-infected children. J Acquir Immune Defic Syndr 2003; 32: 482-9
41. Mulligan K, Grunfeld C, Tai VW, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000; 23: 35-43
42. Carr A, Miller J, Law M, et al. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 2000; 14: F25-32
43. Mallal SA, John M, Moore CB, et al. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000; 14: 1309-61
44. Purnell JQ, Zambon A, Knopp RH, et al. Effect of ritonavir on lipids and post heparin lipase activities in normal subjects. AIDS 2000; 14: 51-7
45. Stein JH, Klein MA, Bellehumeur JL, et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001; 104: 257-62
46. Petit JM, Duong M, Duvillard L, et al. HIV-1 protease inhibitors induce an increase of triglyceride level in HIV-infected men without modification of insulin sensitivity: a longitudinal study. Horm Metab Res 2000; 32: 367-72
47. Periard D, Telenti A, Sudre P, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. Circulation 1999; 100 (7): 700-5
48. Bonnet E, Ruidavets JB, Tuech J, et al. Apoprotein C-III and E-containing lipoprotein particles are markedly increased in HIV-infected patients treated with protease inhibitors: association with the development of lipodystrophy. J Clin Endocrinol Metab 2001; 86 (1): 296-302
49. Baril L, Beucler I, Valantin MA. Low lipolytic enzyme activity in patients with severe hypertriglyceridemia on highly active antiretroviral therapy. AIDS 2001; 15 (3): 415-7
50. Tershakovec AM, Frank I, Rader D. HIV-related lipodystrophy and related factors. Atherosclerosis 2004; 174 (1): 1-10
51. Hadigan C, Meigs JB, Corcoran C, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001; 32: 130-9
52. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000; 275: 20251-4
53. Gnudi L, Shepherd PR, Kahn BB. Over-expression of GLUT4 selectively in adipose tissue in transgenic mice: implication for nutrient partitioning. Proc Nutr Soc 1996; 55: 191-9
54. Katz EB, Stenbit AE, Hatton K, et al. Cardiac and adipose tissue abnormalities but not diabetes in mice deficient in GLUT 4. Nature 1995; 377: 151-5
55. Tsao TS, Stenbit AE, Li J, et al. Muscle-specific transgenic complementation of GLUT4-deficient mice. J Clin Invest 1997; 100: 671-7
56. Mauras N, O'Brien KO, Welch S, et al. Insulin-like growth factor I and growth hormone (GH) treatment in GH-deficient humans: differential effects on protein, glucose, lipid, and calcium metabolism. J Clin Endocrinol Metab 2000; 85: 1686-94
57. Kato Y, Murakami Y, Sohmiya M, et al. Regulation of human growth hormone secretion and its disorders. Inter Med 2002; 41 (1): 7-13
58. Shadid S, Jensen MD. Effects of growth hormone administration in human obesity. Obes Res 2003; 11: 170-5
59. Attallah H, Friedlander AL, Hoffman AR. Visceral obesity, impaired glucose tolerance, metabolic syndrome, and growth hormone therapy. Growth Horm IGF Res 2006; 16 Suppl. A: S62-7
60. Johannsson G, Mårin P, Lönn L, et al. Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure. J Clin Endocrinol Metab 1997; 82 (3): 727-34
61. Franco C, Brandberg J, Lönn L, et al. Growth hormone treatment reduces abdominal visceral fat in postmenopausal women with abdominal obesity: a 12-month placebo-controlled trial. J Clin Endocrinol Metab 2005; 90 (3): 1466-74
62. Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the Growth Hormone Research Society workshop on adult growth hormone deficiency. J Clin Endocrinol Metab 1998; 98 (2): 379-81
63. Carroll PV, Christ ER, Bengtsson B-Å, et al. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. J Clin Endocrinol Metab 1998; 83: 382-95
64. Holmes SJ, Economou G, Whitehouse RW, et al. Reduced bone mineral density in patients with adult onset growth hormone deficiency. J Clin Endocrinol Metab 1994; 78: 669-74
65. Shahi M, Beshyah SA, Hackett D, et al. Myocardial dysfunction in treated adult hypopituitarism: a possible explanation for increased cardiovascular mortality. Br Heart J 1992; 67: 92-6
66. Rosen T, Bengtsson B-Å. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990; 336: 285-8
67. Beshyah SA, Johnston DG. Cardiovascular disease and risk factors in adults with hypopituitarism. Clin Endocrinol 1999; 50 (1): 1-15
68. Menezes Oliveira JL, Marques-Santos C, Barreto-Filho JA, et al. Lack of evidence of premature atherosclerosis in untreated severe isolated growth hormone (GH) deficiency due to a GH-releasing hormone receptor mutation. J Clin Endocrinol Metab 2006; 91 (6): 2093-9
69. Johansson JO, Fowelin J, Landin K, et al. Growth hormone-deficient adults are insulin resistant. Metab Clin Exp 1995; 44: 1126-9
70. Hew FL, Koschmann M, Christopher M, et al. Insulin resistance in growth hormone-deficient adults: defects in glucose utilization and glycogen synthase activity. J Clin Endocrinol Metab 1996; 81: 555-64
71. De Boer H, Blok GJ, Voerman HJ, et al. Serum lipid levels in growth hormone-deficient men. Metab Clin Exp 1994; 43: 199-203
72. Molitch ME, Clemmons DR, Malozowski S, et al. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2006; 91 (5): 1621-34
73. Monson JP. Long-term experience with GH replacement therapy: efficacy and safety. Eur J Endocrinol 2003; 148 Suppl. 2: S9-14
74. Benedini S, Dalle Carbonare L, Albiger N, et al. Effect of short-term therapy with recombinant human growth hormone (GH) on metabolic parameters and preclinical atherosclerotic markers in hypopituitary patients with growth hormone deficiency. Horm Metab Res 2006; 38 (1): 16-21
75. Colao A, Di Somma C, Savanellia MC, et al. Beginning to end: cardiovascular implications of growth hormone (GH) deficiency and GH therapy. Growth Horm IGF Res 2006; 16 Suppl.: 41-8
76. Svensson J, Bengtsson B-Å, Taskinen MR, et al. A nine-month, placebo-controlled study of the effects of growth hormone treatment on lipoproteins and LDL size in abdominally obese men. Growth Horm IGF Res 2000; 10 (3): 118-26
77. Gola M, Bonadonna S, Doga M, et al. Growth hormone and cardiovascular risk factors. J Clin Endocrinol Metab 2005; 90 (3): 1864-70
78. Drake WM, Howell SJ, Monson JP, et al. Optimizing gh therapy in adults and children. Endocr Rev 2001 Aug; 22 (4): 425-50
79. Jenkins PJ, Bustin SA. Evidence for a link between IGF-I and cancer. Eur J Endocrinol 2004; 151 Suppl. 1: S17-22
80. Renehan AG, Toogood AA, Ryder WD, et al. Paradoxical elevations in serum IGF II and IGF binding protein-2 in acromegaly: insights into the regulation of these peptides. Clin Endocrinol (Oxf) 2001; 55 (4): 469-75
81. Allen DB, Rundle AC, Graves DA, et al. Risk of leukemia in children treated with human growth hormone: review and reanalysis. J Pediatr 1997; 131: S32-6
82. Wilton P. Adverse events during growth hormone treatment: 10 years experience in KIGS, a pharmacoepidemiological study. In: Ranke MB, editor. Growth hormone therapy in KIGS: 10 years experience. Leipzig: Johann Ambrosius Barth Verlag, 1999
83. Shalet SM, Brennan BM, Reddingius RE. Growth hormone therapy and malignancy. Horm Res 1997; 48 Suppl. 4: 29-32
84. Gibney J, Johannsson G. Safety of growth hormone replacement therapy in adults. Expert Opin Drug Saf 2004 Jul; 3 (4): 305-16
85. Ergun-Longmire B, Mertens AC, Mitby P, et al. Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. J Clin Endocrinol Metab 2006; 91 (9): 3494-8
86. Blethen SL, Allen DB, Graves D, et al. Safety of recombinant deoxyribonucleic acid-derived growth hormone: the National Cooperative Growth Study experience. J Clin Endocrinol Metab 1996; 81: 1704-10
87. Cutfield WS, Wilton P, Bennmarker H, et al. Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment. Lancet 2000; 355: 610-3
88. Jenkins PJ, Mukherjee A, Shalet SM. Does growth hormone cause cancer? Clin Endocrinol (Oxf) 2006; 64 (2): 115-21
89. Crawford BA, Cowell CT, Greenacre P, et al. Carbohydrate metabolism on high dose growth hormone therapy in children treated for leukaemia. Aust Paediatr J 1989; 25: 236-40
90. Botero D, Danon M, Brown RS. Symptomatic non-insulin-dependent diabetes mellitus during therapy with recombinant human growth hormone. J Pediatr 1993; 123: 590-2
91. Svensson J, Fowelin J, Landin K, et al. Effects of seven years of GH-replacement therapy on insulin sensitivity in GH-deficient adults. J Clin Endocrinol Metab 2002; 87: 2121-7
92. Veldhuis JD, Liem AY, South S, et al. Differential impact of age, sex steroid hormones, and obesity on basal versus pulsatile growth hormone secretion in men as assessed in an ultrasensitive chemiluminescence assay. J Clin Endocrinol Metab 1995; 80: 3209-22
93. Veldhuis JD, Iranmanesh A, Ho KK, et al. Dual defects in pulsatile growth hormone secretion and clearance subserve the hyposomatotropism of obesity in man. J Clin Endocrinol Metab 1991; 72: 51-9
94. Ghigo E, Procopio M, Boffano GM, et al. Arginine potentiates but does not restore the blunted growth hormone response to growth-hormone releasing hormone in obesity. Metabolism 1992; 41: 560-3
95. Saint-Marc T, Touraine JL. Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy. AIDS 1999; 2813 (8): 1000-2
96. Koutkia P, Canavan B, Breu J, et al. Effects of growth hormone-releasing hormone on bone turnover in human immunodeficiency virus-infected men with fat accumulation. J Clin Endocrinol Metab 2005; 90 (4): 2154-60
97. Kotler DP, Muurahainen N, Grunfeld C, et al. Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients. Serostim in Adipose Redistribution Syndrome Study Group. J Acquir Immune Defic Syndr 2004; 1;35 (3): 239-52
98. Andersen O, Haugaard SB, Hansen BR, et al. Different growth hormone sensitivity of target tissues and growth hormone response to glucose in HIV-infected patients with and without lipodystrophy. Scand J Infect Dis 2004; 36 (11-12): 832-9
99. Haugaard SB, Andersen O, Hansen BR, et al. Insulin-like growth factors, insulin-like growth factor-binding proteins, insulin-like growth factor-binding protein-3 protease, and growth hormone-binding protein in lipodystrophic human immunodeficiency virus-infected patients. Metabolism 2004; 53 (12): 1565-73
100. Scacchi M, Pincelli AI, Cavagnini F, et al. Growth hormone in obesity. Int J Obes Relat Metab Disord 1999; 23 (3): 260-71
101. Sutinen J, Kannisto K, Korsheninnikova E, et al. In the lipodystrophy associated with highly active antiretroviral therapy, pseudo-Cushing's syndrome is associated with increased regeneration of cortisol by 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue. Diabetologia 2004 Oct; 47 (10): 1668-71
102. Ricketts ML, Verhaeg JM, Bujalska I, et al. Immunohistochemical localization of type 1 11β-hydroxysteroid dehydrogenase in human tissues. J Clin Endocrinol Metab 1998; 83: 1325-35
103. Bujalska IJ, Kumar S, Hewison M, et al. Differentiation of adipose stromal cells: the roles of glucocorticoids and 11β-hydroxysteroid dehydrogenase. Endocrinology 1999; 140: 3188-96
104. Bujalska IJ, Kumar S, Stewart PM. Does central obesity reflect "Cushing's disease of the omentum"? Lancet 1997; 349: 1210-3
105. Tomlinson JW, Sinha B, Bujalska I, et al. Expression of 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue is not increased in human obesity. J Clin Endocrinol Metab 2002; 87: 5630-563
106. Filipsson H, Monson JP, Koltowska-Häggström M, et al. The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. J Clin Endocrinol Metab 2006; 91 (10): 3954-61
107. He Q, Engelson ES, Albu JB, et al. Preferential loss of omental-mesenteric fat during growth hormone therapy of HIV-associated lipodystrophy. J Appl Physiol 2003; 94 (5): 2051-7
108. Tomlinson JW, Crabtree N, Clark PM, et al. Low-dose growth hormone inhibits 11 beta-hydroxysteroid dehydrogenase type 1 but has no effect upon fat mass in patients with simple obesity. J Clin Endocrinol Metab 2003; 88 (5): 2113-8
109. Stewart PM, Toogood AA, Tomlinson JW. Growth hormone, insulin-like growth factor-I and the cortisol-cortisone shuttle. Horm Res 2001; 56 Suppl. 1: 1-6
110. Lauriola V. Effects of physical exercise in lipodystrophy HIV-related on metabolic parameters [in Italian; thesis]. Milan: Faculty of Exercise Sciences, University of Study of Milan, 2007 Mar
111. Abdu TA, Neary R, Elhadd TA, et al. Coronary risk in growth hormone deficient hypopituitary adults: increased predicted risk is due largely to lipid profile abnormalities. Clin Endocrinol (Oxf) 2001; 55 (2): 209-16
112. Haugaard SB, Andersen O, Flyvbjergd A, et al. Growth factors, glucose and insulin kinetics after low dose growth hormone therapy in HIV-lipodystrophy. J Infect 2006; 52 (6): 389-98